Caution has been raised in a paper published by the Alliance for Safe Biologic Medicines over recent developments affecting biosimilars in the US, particularly in regard to the regulatory approach to biosimilar switching and interchangeability.
The ASBM styles itself as “an organization composed of diverse healthcare groups and individuals” who are “working together to ensure...






